Harris M W, Birnbaum L S
Systemic Toxicology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709.
Fundam Appl Toxicol. 1989 Apr;12(3):442-8. doi: 10.1016/0272-0590(89)90018-3.
Perfluorodecanoic acid (PFDA) is a representative of the perfluorinated carboxylic acids used as commercial wetting agents and flame retardants. Signs of PFDA toxicity have been reported to resemble those seen after exposure to TCDD. To determine if PFDA exhibits teratogenic effects similar to those of TCDD or is a developmental toxin, time-mated C57BL/6N mice were administered PFDA by gavage in corn oil (10 ml/kg) on gestation days (gd) 10-13 or gd 6-15 at levels of 0, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, or 32.0 mg/kg/day or 0, 0.03, 0.3, 1.0, 3.0, 6.4, or 12.8 mg/kg/day, respectively. Dams were killed on gd 18 and maternal and fetal toxicity was assessed. Fetuses were examined for external, visceral, or skeletal malformations. Maternal body weight gain (corrected for the weight of the gravid uterus) was significantly reduced as a result of PFDA treatment at 6.4 and 12.8 mg/kg/day (gd 6-15) and 16.0 and 32.0 mg/kg/day (gd 10-13). Fetal viability was decreased only in those groups showing extensive maternal body weight loss. Fetal body weights were significantly reduced at levels as low as 0.1 mg/kg/day (gd 6-15) and 0.5 mg/kg/day (gd 10-13). No hydronephrosis, cleft palate, or edema was observed nor were any other soft tissue or skeletal malformations detected. Thus, PFDA does not produce malformations in C57BL/6N mice, and the developmental toxicity observed (increased fetal mortality and decreased live fetal body weight) was seen only at doses that were maternally toxic.
全氟癸酸(PFDA)是用作商业湿润剂和阻燃剂的全氟羧酸的代表。据报道,PFDA的毒性迹象与接触2,3,7,8-四氯二苯并对二噁英(TCDD)后出现的迹象相似。为了确定PFDA是否表现出与TCDD类似的致畸作用或是否为发育毒素,在妊娠第10 - 13天或第6 - 15天,将经时间交配的C57BL/6N小鼠通过灌胃给予玉米油(10 ml/kg)中的PFDA,剂量分别为0、0.25、0.5、1.0、2.0、4.0、8.0、16.0或32.0 mg/kg/天或0、0.03、0.3、1.0、3.0、6.4或12.8 mg/kg/天。在妊娠第18天处死母鼠并评估母体和胎儿毒性。检查胎儿的外部、内脏或骨骼畸形。由于在6.4和12.8 mg/kg/天(妊娠第6 - 15天)以及16.0和32.0 mg/kg/天(妊娠第10 - 13天)给予PFDA治疗,母体体重增加(校正妊娠子宫重量)显著降低。仅在那些显示母体体重大量减轻的组中胎儿活力降低。在低至0.1 mg/kg/天(妊娠第6 - 15天)和0.5 mg/kg/天(妊娠第10 - 13天)的水平下,胎儿体重显著降低。未观察到肾盂积水、腭裂或水肿,也未检测到任何其他软组织或骨骼畸形。因此,PFDA在C57BL/6N小鼠中不会产生畸形,并且观察到的发育毒性(增加的胎儿死亡率和降低的活胎体重)仅在对母体有毒的剂量下出现。